Posts

SGN-1 by Guangzhou Sinogen Pharmaceutical for Head And ...

Dec 4, 2023

SGN-1 is under clinical development by Guangzhou Sinogen Pharmaceutical and curr...

RiMO-301 by Rimo Therapeutics for Recurrent Head And Ne...

Dec 4, 2023

RiMO-301 is under clinical development by Rimo Therapeutics and currently in Pha...

AZ-3102 by Azafaros for Niemann-Pick Disease Type C: Li...

Dec 4, 2023

AZ-3102 is under clinical development by Azafaros and currently in Phase II for ...

J-2H1702 by J2H Biotech for Metabolic Dysfunction-Assoc...

Dec 4, 2023

J-2H1702 is under clinical development by J2H Biotech and currently in Phase II ...

NN-9440 by Inversago Pharma for Metabolic Syndrome: Lik...

Dec 4, 2023

NN-9440 is under clinical development by Inversago Pharma and currently in Phase...

Opinion: STAT readers on burnt-out infectious disease doctors, 12-month prescriptions, and counting disabled Americans

Opinion: STAT readers on burnt-out infectious disease d...

Dec 3, 2023

Letters to the editor: “It's no wonder that ID doctors are some of the most burn...

STAT+: Takeda, Janssen join wearable maker to measure scratching, and other health tech news

STAT+: Takeda, Janssen join wearable maker to measure s...

Dec 3, 2023

In the latest edition of Health Tech newsletter: Takeda, Janssen team up with Ac...

STAT+: Do GLP-1s have a future treating alcoholism?

STAT+: Do GLP-1s have a future treating alcoholism?

Dec 3, 2023

Want to stay on top of the science and politics driving biotech today? Sign up t...

Needle-free ultrasound vaccine delivery #Acoustics23

Needle-free ultrasound vaccine delivery #Acoustics23

Dec 3, 2023

SYDNEY, Dec. 4, 2023 – An estimated quarter of adults and two-thirds of children...

Lung Cancer Data from AbbVie Paves Way for Accelerated ADC Approval, Falls Below Initial Benchmark

Lung Cancer Data from AbbVie Paves Way for Accelerated ...

Dec 2, 2023

AbbVie is actively seeking accelerated approval for its promising c-Met antibody...

Navigating affordable approaches to cell therapy clinical trials

Navigating affordable approaches to cell therapy clinic...

Dec 2, 2023

By Luisa Sterkel & Joana Loureiro, Tenthpin Consultants and Dr. Frank Altznauer...

Biocon integrates Viatris biosimilars in 31 European countries

Biocon integrates Viatris biosimilars in 31 European co...

Dec 2, 2023

Biocon subsidiary Biocon Biologics has successfully integrated Viatris' biosimi...

AstraZeneca’s durvalumab recommended for bile duct cancers

AstraZeneca’s durvalumab recommended for bile duct cancers

Dec 2, 2023

The Scottish Medicines Consortium and the UK's National Institute of Health and...

FDA accepts Merck’s Keytruda plus Padcev sBLA to treat urothelial cancer

FDA accepts Merck’s Keytruda plus Padcev sBLA to treat ...

Dec 2, 2023

The US Food and Drug Administration (FDA) has accepted Merck (MSD)’s new supple...

Teva and Sanofi conclude collaboration deal for anti-TL1A therapy

Teva and Sanofi conclude collaboration deal for anti-TL...

Dec 2, 2023

Teva Pharmaceuticals and Sanofi have concluded a collaboration deal for co-deve...

Signal: Novo Nordisk sues more Florida pharmacies in battle against fake semaglutide

Signal: Novo Nordisk sues more Florida pharmacies in ba...

Dec 2, 2023

Novo Nordisk, manufacturer of blockbuster drugs Ozempic and Wegovy, announced W...